ProMIS Neurosciences Reports Top-Line Data From The First Four Cohorts Of Its First-In-Human Phase 1a Clinical Trial Of PMN310 In Healthy Volunteers For Alzheimer's Disease Patients; Topline Results Demonstrated A Favorable Safety Profile And...
ProMIS Neurosciences Reports Top-Line Data From The First Four Cohorts Of Its First-In-Human Phase 1a Clinical Trial Of PMN310 In Healthy Volunteers For Alzheimer's Disease Patients; Topline Results Demonstrated A Favorable Safety Profile And...
ProMIS Neurosciences Reports Top-Line Data From The First Four Cohorts Of Its First-In-Human Phase 1a Clinical Trial Of PMN310 In Healthy Volunteers For Alzheimer's Disease Patients; Topline Results Demonstrated A Favorable Safety Profile And Tolerability Across Four Ascending Dose Levels
ProMIS神經科學公司報告了PMN310在健康志願者中用於治療阿爾茨海默病的一期臨床試驗的前四組的頭條數據；前期結果展示了通過四種不斷升級的劑量水平達到了安全性，耐受性較好的結果。
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer's disease patients
前期結果在健康志願者中展示了四種遞增劑量水平方面的有利安全特徵和耐受性，並且展示出Cerebrospinal fluid (CSF)中的PMN310抗體具有劑量依賴性，顯示出其在治療阿爾茨海默病患者中潛在的作用。
CAMBRIDGE, Massachusetts and TORONTO, Ontario, July 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced positive top-line data from the first four cohorts of its first-in-human Phase 1a clinical trial of PMN310 in healthy volunteers.
馬薩諸塞州劍橋和安大略省多倫多，2024年7月26日（環球新聞線）--ProMIS神經科學公司（納斯達克股票代碼：PMN）是一家生物技術公司，專注於生成和開發治療神經退行性疾病如阿爾茨海默病（AD）、肌萎縮側索硬化（ALS）、多系統萎縮症（MSA）等靶向有毒錯構蛋白質抗體治療劑；今天，該公司宣佈其PMN310在健康志願者中一期臨床試驗的前四組通過頭條數據審核。
The Phase 1a clinical data, which has been collected and analyzed from the first four of five cohorts, indicated that PMN310 demonstrated a favorable safety profile, was well tolerated and, importantly, crossed the blood brain barrier in healthy volunteers, in a dose dependent manner and at concentrations that suggest sufficient target engagement in the planned follow-on clinical trial in Alzheimer's patients.
這一第一階段臨床數據是收集和分析其中5組的前4組，表明PMN310具有良好的安全性和耐受性，而且以劑量依賴性的方式穿過健康志願者的血腦屏障，濃度足以表明在計劃的隨機臨床試驗中，已經充分攻擊了靶點並展示了良好的效果。
譯文內容由第三人軟體翻譯。